In fact, EP-NECs at different sites of origin have a variable prevalence of “site-specific” molecular features, mainly shared with non-neuroendocrine cancers from the same organs, as well as of TP53 and RB1 mutations (virtually ubiquitous in SCLC) [8,35,36,37]. Here, TP53 is linked to neuroendocrine carcinoma.